<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570412</url>
  </required_header>
  <id_info>
    <org_study_id>Aldox Compassionate Use</org_study_id>
    <nct_id>NCT02570412</nct_id>
  </id_info>
  <brief_title>Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy</brief_title>
  <official_title>Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <brief_summary>
    <textblock>
      Compassionate use of aldoxorubicin in sarcoma patients who have failed prior chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a compassionate use protocol allowing sarcoma patients that have relapsed after prior
      therapies and are not eligible for other protocols involving the evaluation of aldoxorubicin
      to receive aldoxorubicin.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aldoxorubicin</intervention_name>
    <description>aldoxorubicin administered at 350 mg/m2</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or unrectable sarcoma that has either relapsed or was refractory to at leat
             1 prior chemotherapy or immunotherapy regimen and for which no standard approved
             therapy exists

          -  Must not be eligible for another CytRx-sponsored clinical trial

          -  Able to provide complete medical records for review by the CytRx Medical Monitor

          -  Able to receive treatment at a site that is participating or has participated in
             another CytRx-sponsored aldoxorubicin trial

          -  Capable of providing informed consent and complying with trial procedures

          -  ECOG performance status 0-2

          -  Measurable or evaluable tumor lesions according to RECIST 1.1 criteria

          -  Women must not be able to become pregnant (eg post-menopausal for at least 1 year,
             surgically sterile, or practicing adequate birth control methods) for the duration of
             the study

          -  Women of child bearing potential must have a negative serum or urine pregnancy test at
             the Screening Visit and be non-lactating

        Exclusion Criteria:

          -  Chemotherapy, palliative surgery and/or radiation treatment less than 30 days prior to
             screening for non-target lesion

          -  Exposure to any investigational agent within 30 days of screening

          -  Central nervous system metastases that are symptomatic

          -  Laboratory values: Screening serum creatinine &gt;1.5×ULN, ALT &gt;3×ULN, or &gt;5×ULN if liver
             metastases are present, total bilirubin &gt;3×ULN, ANC &lt;1,500/mm3, platelet concentration
             &lt;100,000/mm3, hematocrit level &lt;25% for females or &lt;27% for males, coagulation tests
             (PT, PTT, INR) &gt;1.5×ULN

          -  Anion gap &gt; 16 meq/L or arterial or venous blood pH &lt; 7.30.

          -  Clinically evident congestive heart failure &gt; class II of the New York Heart
             Association (NYHA) guidelines

          -  Current serious, clinically significant cardiac arrhythmias, defined as the existence
             of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V

          -  Baseline QTc &gt;470 msec and/or previous history of QT prolongation while taking other
             medications. Concomitant use of medications associated with a high incidence of QT
             prolongation is not allowed

          -  History or signs of active coronary artery disease with or without angina pectoris.

          -  Serious myocardial dysfunction defined scintigraphically (eg MUGA, myocardial
             scintigram) or ultrasound determined absolute LVEF &lt;45% of predicted

          -  History of HIV infection

          -  Active, clinically signifiant serious infection requiring treatment with antibiotics,
             anti-virals or anti-fungals

          -  Major surgery within 3 weeks prior to enrollment

          -  Substance abuse or any condition that might interfere with the subject's participation
             in the study or in the evaluation of the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

